BackGlobal Blood Therapeutics Overview

Global Blood Therapeutics Current Cash

Global Blood Therapeutics's current cash is $260M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$261.15M
37.72% YoYΔ $-158.16M vs prior year quarter

Peer average

Loading

Global Blood Therapeutics Current Cash History

Loading

Global Blood Therapeutics vs. peers: Current Cash Comparison

Loading

Global Blood Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Global Blood Therapeutics (GBT) FAQ

As of the most recent data (June 2022), GBT shows a current cash of $260M. That compares with $420M in the prior-year period — down 37.7% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GBT's current cash is now $260M (was $420M) — a 37.7% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Global Blood Therapeutics is outperforming or lagging.

Tracking GBT's current cash over time shows whether Global Blood Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $260M That compares with $420M in the prior-year period — down 37.7% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Global Blood Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $260M) with ownership activity and broader fundamentals.

Global Blood Therapeutics's current cash is $260M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.